Biodiversity Interventions for Well-Being

Status Active, not recruiting

Clinical Trial Summary

Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities, which weakens the functionality of the urban ecosystems and the well-being of citizens. This may also increase the risk of immune-mediated disorders among urban dwellers. In Biodiversity interventions for well-being (BIWE), microbial biodiversity interventions are performed to increase biodiversity in urban built areas. Results from the intervention trials are combined with publicly available land cover and ecological data. These are analyzed from the viewpoint of shifts in ecosystems and human well-being and immune regulation, ecological quality, and urban planning. The investigators set up an intervention study in which urban private yards are rewilded with diverse vegetation and decaying deadwood and plant residuals. The investigators aim to evaluate the effect of rewilding, and yard management practices on commensal microbiome, cortisol levels and well-being and salivary cytokine levels, and gene pathways.

Clinical Trial Description

Our specific aims are: To assess if rewilding diversifies health-associated skin microbiota and is associated with salivary cytokine levels, gene pathways, cortisol levels and commensal microbiota. Assess whether there are patterns in the microbiome associated with the salivary cytokine levels and hair cortisol levels. Assess whether rewilding affects health and psychological measures, such as Perceived Stress Scale (PSS), Warwick-Edinburgh Mental Wellbeing Scale (SWEMWS), Depression Scale (DEPS) and Nature Relatedness Scale (NR6). The investigators will recruit approximately 42 (21 study subjects per treatment) subjects living in a detached house or terraced house in urban areas and aged between 18-72. The medical exclusion criteria include immunosuppressive medications, immune deficiencies, a disease affecting immune response (e.g., colitis ulcerosa, rheumatoid arthritis, Crohn's disease, diabetes), cancer diagnosis within the last year or on-going cancer treatment. Other exclusion criteria include incompetency and living outside city area. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06353035
Study type	Interventional
Source	Natural Resources Institute Finland
Contact
Status	Active, not recruiting
Phase	N/A
Start date	March 30, 2022
Completion date	September 30, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05414994` - Assessment of the Ocular Microbiome in Health and Disease
Completed	`NCT04769882` - Er:YAG Laser Effects on Microbial Population in Conservative Dentistry	N/A
Completed	`NCT04766528` - Effect of Diet on the Microbiota / Endoccanabinoidome Axis in Response to Physical Activity	N/A
Completed	`NCT03720314` - Microbiota Profiling in IBS
Completed	`NCT04122612` - Shaping Microbiome in the First 1,000 Days of Life
Not yet recruiting	`NCT05405634` - Microbiota in Chronic Anal Fissure and Its Association With Prognosis
Not yet recruiting	`NCT04895774` - Ex Vivo Study of the Mechanism of Action of Active Ingredients on the Intestinal Microbiota
Recruiting	`NCT05992688` - The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)	N/A
Recruiting	`NCT05502380` - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery	Phase 3
Completed	`NCT05175833` - Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19	Phase 2
Recruiting	`NCT04836910` - Microbiome and Polycystic Ovaries
Recruiting	`NCT05603650` - Effects of Mouthrinses on the Microbiome of the Oral Cavity and GI Tract	N/A
Completed	`NCT04991818` - MSC - OneBiome UX Pilot Study	N/A
Completed	`NCT05575050` - Impact of Teeth Brushing in Ventilated COVID-19 Patients.	N/A
Completed	`NCT04374955` - The Effect of Probiotic Added to Maternal Diet on Infantile Colic and Intestinal Microbiota Content	N/A
Recruiting	`NCT04140747` - Transfer of Strictly Anaerobe Microbes From Mother to Child
Recruiting	`NCT04111471` - The Use of A Prebiotic to Promote a Healthy Gut Microbiome in Pediatric Stem Cell Transplant Recipients	N/A
Suspended	`NCT03220282` - The Milk, Growth and Microbiota Study	N/A
Completed	`NCT03422562` - Probiotics and Intestinal Microbiome in Preterm Infants	Phase 3
Recruiting	`NCT05695196` - Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Biodiversity Interventions for Well-Being — BIWE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms